Related to Mitomics Signs Up Bostwick to Market Mitochondrial DNA-Based Prostate Cancer Test

• Responding to H7N9 Threat, FDA Issues Emergency Use Authorization for CDC RT-PCR Diagnostic
  
• Foundation Medicine Taps Sloan-Kettering Clinical, Genomics Expertise to Develop New MDx
  
• New International Collaboration Aims to Develop Drugs, Diagnostics, More
  
• Analytik Jena Acquires Sepsis Test Among SIRS-Lab Assets
  
• Two Animal Diagnostics Firms Take on France
  
• VC Investment: Not Quite Dead?
  
• Bayer Prostate Cancer Drug Gains FDA Approval
  
• NIH Grant Won Toward Developing ASD, Mental Illness Gene-Seeking Software
  
• Mayo Clinic, Cancer Genetics Form Diagnostics JV
  
• Health Discovery Enters Deals with Abbott and Quest Diagnostics for Prostate Cancer Tests
  
• Epigenomics Grants Predictive Biosciences Rights to Use a Biomarker in a Prostate Cancer Test
  
• Sangretech Gives Bostwick Scientific Rights to Its Dendritic-Cell Technology
  
• Protagen Taps Scienion for Biomarker Panel Validation Work
  
• Prostate Cancer Foundation to Help Exosome Diagnostics Fortify Development of Exosome Biofluid Test
  
• FDA Clears Gen-Probe’s PCA3 Urine Assay for Predicting Need for Repeat Prostate Biopsies
  
• Plus Diagnostics to Co-Market MDxHealth’s ConfirmMDx Prostate Cancer Test in the U.S.
  
• Myriad Taps Intermountain Healthcare to Help Validate Prostate Cancer Diagnostic
  
• FDA Clears Beckman Coulter’s phi Blood Test for Prostate Cancer
  
• Empire Genomics Nabs Prostate Cancer Biomarker from Cornell
  
• QDx to Market Mitomics’ Prostate Cancer Diagnostic